PolyPid Ltd. Reports Positive Q2 Earnings: Strong Balance Sheet, Successful Trials and Future Growth Plans

PolyPid Ltd.'s Q2 earnings call highlighted successful trial results for D-PLEX100, a 38% reduction in primary endpoint and 58% reduction in surgical site infections in abdominal colorectal surgeries. The company reported a strengthened balance sheet with $29.5 million in cash and cash equivalents and plans to submit a New Drug Application to the FDA in early 2026. Despite increased expenses and a widened net loss, PolyPid remains focused on its long-term growth strategy.